Study of Golidocitinib Combined With Selinexor for Treating Chronic Active Epstein-Barr Virus Disease CAEBVD A Multicenter, Prospective, Single-Arm Clinical Trial

What this Trial Is About

Researchers are evaluating a combined treatment using golidocitinib and selinexor for patients with Chronic Active Epstein-Barr Virus Disease CAEBVD. This multicenter, prospective, single-arm clinical study aims to assess the effectiveness of this treatment approach. The study is led by Beijing Friendship Hospital and focuses on improving disease activity and viral levels in affected patients. Participants will receive golidocitinib at a dose of 150 mg once daily and selinexor at 40 mg once weekly. This combination therapy is given during the treatment period, with patients monitored closely for response and safety. The study does not include multiple groups or placebo comparison, focusing solely on this experimental treatment. During the study, participants will undergo evaluations of disease activity and Epstein-Barr virus DNA levels eight weeks after starting treatment. Researchers will monitor various health parameters including blood tests and liver and kidney function to ensure safety and treatment adherence. The trial will continue to follow participants until the planned end date, allowing detailed assessment of treatment effects and participant well-being.

Golidocitinib Combined With Selinexor for CAEBVD